#Japan #Tokyo #COVID-19 vaccine #mRNA Technology #Moderna Japan

Moderna Japan's New COVID-19 Vaccine Approval

In a significant milestone in the fight against COVID-19, Moderna Japan has announced that it has obtained manufacturing and sales approval for its new vaccine, Emnex Spike® (injectable syringe for ages 12 and above), specifically aimed at preventing infections caused by SARS-CoV-2. This newly approved vaccine is set to provide a promising new option for immunization against the ongoing pandemic.

About the Vaccine

The Emnex Spike® vaccine is designed to be administered in a single dose of 0.2 mL, containing 10μg of mRNA, which is one-fifth of the amount contained in the previously released Spikevax® vaccine for ages 12 and up. This mRNA component is crucial as it helps instruct the immune system on how to fight the virus effectively.

The approval came after extensive studies, including a domestic Phase III trial (mRNA-1283 P301 study Japan cohort), which assessed the vaccine's immunogenicity and safety in Japanese subjects. The positive results led to its approval for use against SARS-CoV-2 infection.

Global Context and Future Plans

Emnex Spike® is not just another vaccine; it has been in use in the United States since 2025. The vaccine has already garnered regulatory approval in other regions, including the EU, Canada, and Australia, indicating a robust global strategy for Moderna as it expands its reach.

As part of its commitment to public health, Moderna Japan aims to begin supplying the Emnex Spike® vaccine to the Japanese population around Autumn 2026. To make this possible, the company is working closely with various stakeholders to ensure a smooth launch.

Moderna's Vision and Mission

Moderna has established itself as an innovative leader in the field of mRNA therapeutics. Since its inception, the company has revolutionized the manufacturing process of pharmaceuticals, continuously transforming approaches to disease treatment and prevention. Its unique mRNA platform enables the development of vaccines and therapeutics for a broad range of diseases, including infections, cancer, and rare conditions.

Furthermore, Moderna prides itself on its corporate culture and values, fostering a mindset that emphasizes collaboration among its global workforce. The collective effort is aimed at contributing to the health of individuals worldwide while maximizing the impact of mRNA medicines.

For more information about Moderna and its significant contributions to health care, visit modernatx.com. Don't forget to follow them on social media platforms like X, Facebook, Instagram, YouTube, and LinkedIn to stay updated on their latest developments and initiatives.